Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-2440cbc7bcf5f09685459c4222f929e1",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-2440cbc7bcf5f09685459c4222f929e1",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-2440cbc7bcf5f09685459c4222f929e1",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-2440cbc7bcf5f09685459c4222f929e1\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-2440cbc7bcf5f09685459c4222f929e1</b></p><a name=\"composition-en-2440cbc7bcf5f09685459c4222f929e1\"> </a><a name=\"hccomposition-en-2440cbc7bcf5f09685459c4222f929e1\"> </a><a name=\"composition-en-2440cbc7bcf5f09685459c4222f929e1-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1072/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - spectrila</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/15/1072/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp2440cbc7bcf5f09685459c4222f929e1"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - spectrila",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Spectrila is and what it is used for</li><li>What you need to know before you are given Spectrila</li><li>How to use Spectrila</li><li>Possible side effects</li><li>How to store Spectrila</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What spectrila is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What spectrila is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Spectrila contains asparaginase, which is an enzyme that interferes with natural substances necessary for cancer cell growth. All cells need an amino acid called asparagine to stay alive. Normal cells can make asparagine for themselves, while some cancer cells cannot. Asparaginase lowers asparagine level in blood cancer cells and stops the cancer growing.</p><p>Spectrila is used to treat adults and children with acute lymphoblastic leukaemia (ALL) which is a form of blood cancer. Spectrila is used as part of a combination therapy.</p></div>"
}
},
{
"title" : "2. What you need to know before you take spectrila",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take spectrila"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Spectrila must not be used</p><ul><li>if you are allergic to asparaginase or to the other ingredient of this medicine (listed in section 6),</li><li>if you have or previously had inflammation of the pancreas (pancreatitis),</li><li>if you have severe liver function problems,</li><li>if you have a blood clotting disorder (such as haemophilia),</li><li>if you had severe bleeding (haemorrhage) or severe blood clotting (thrombosis) under previous asparaginase treatment.</li></ul><p>Warnings and precautions Talk to your doctor or nurse before you are given Spectrila.</p><p>The following life-threatening situations could arise during treatment with Spectrila:</p><ul><li>severe inflammation of the pancreas (acute pancreatitis),</li><li>liver problems,</li><li>a serious allergic reaction which causes difficulty in breathing or dizziness,</li><li>blood clotting disorders (bleeding or formation of blood clots),</li><li>high blood sugar levels.</li></ul><p>Before and during treatment with Spectrila your doctor will carry out blood tests.</p><p>If severe liver problems occur, treatment with Spectrila must be interrupted immediately.</p><p>If allergic symptoms occur, intravenous infusion of Spectrila must be discontinued immediately. You may be given anti-allergic medicines and, if necessary, medicines to stabilise your circulation. In the majority of cases, your treatment can be continued by switching to other medicines containing different forms of asparaginase.</p><p>Blood clotting disorders may require you to receive fresh plasma or a certain type of protein (antithrombin III) in order to reduce the risk of bleeding or formation of blood clots (thrombosis).</p><p>High blood sugar levels may require treatment with intravenous fluids and/or insulin.</p><p>Reversible posterior leukoencephalopathy syndrome (characterised by headache, confusion, seizures and visual loss) may require blood-pressure lowering medicines and in case of seizure, anti-epileptic treatment.</p><p>Other medicines and Spectrila Tell your doctor if you are using, have recently used or might use any other medicines. This is important as Spectrila may increase the side effects of other medicines through its effect on the liver which plays an important role in removing medicines from the body.</p><p>In addition, it is especially important to tell your doctor if you are also using any of the following medicines:</p><ul><li>Vincristine (used to treat certain types of cancer) since the simultaneous use of vincristine and asparaginase may increase the risk of certain side effects. To avoid this, vincristine is usually given 3 24 hours before asparaginase.</li><li>Glucocorticoids (anti-inflammation medicines that dampen down your immune system) since the simultaneous use of glucocorticoids and asparaginase may increase the formation of blood clots (thrombosis).</li><li>Medicines that reduce the ability of blood to clot, such as anticoagulants (e.g. warfarin and heparin), dipyridamole, acetylsalicylic acid or medicines to treat pain and inflammation, since using these medicines with asparaginase may increase the risk of bleeding.</li><li>Medicines which are metabolised in the liver (e.g. paracetamol, acetylsalicylic acid, tetracycline) because the risk of side effects may increase.</li><li>Asparaginase may influence the efficacy of methotrexate or cytarabine (used to treat certain types of cancer):</li></ul><ul><li>if asparaginase is given after these medicines their effect may be increased.</li><li>if asparaginase is given before these medicines their effect may be weakened.</li></ul><ul><li>Medicines which may have a negative effect on liver function (e.g. paracetamol, acetylsalicylic acid, tetracycline) since these negative effects may be worsened by parallel treatment with asparaginase.</li><li>Medicines which may suppress bone marrow function (e.g. cyclophosphamide, doxorubicin, methotrexate) as these effects may be enhanced by parallel use of asparaginase. You may be more prone to infections.</li><li>Other anti-cancer medicines as they may contribute to the release of too much uric acid when tumour cells are destroyed by asparaginase.</li></ul><p>Vaccination Simultaneous vaccination with live vaccines may increase the risk of a serious infection. You should therefore not receive vaccination with live vaccines until at least 3 months after the end of treatment with Spectrila.</p><p>Pregnancy and breast-feeding<br/>There are no data on the use of asparaginase in pregnant women. Spectrila should not be used during pregnancy unless the clinical condition of the woman requires treatment with asparaginase. It is unknown whether asparaginase is present in human breast milk. Therefore, Spectrila must not be used during breast-feeding.<br/>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p>If you are a woman you must use contraceptives or remain abstinent during chemotherapy and for 7 months after the end of treatment. Since an indirect interaction between components of the oral contraception and asparaginase cannot be ruled out, oral contraceptives are not considered sufficiently safe. A method other than oral contraceptives should be used in women of childbearing potential.</p><p>If you are a man, you should take adequate precautions to ensure that your partner does not become pregnant during your treatment with Spectrila and for 4 months after the last dose.</p><p>Driving and using machines Do not drive or use machines when taking this medicine because it may make you feel drowsy, tired or confused.</p></div>"
}
},
{
"title" : "3. How to take spectrila",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take spectrila"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Spectrila is prepared and given by healthcare personnel. Your doctor decides on the dose you receive. The dose depends on your body surface area (BSA) which is calculated from your height and weight.</p><p>Spectrila is given into a vein. It is usually given with other anti-cancer medicines. The duration of treatment depends on the specific chemotherapy protocol that is used to treat your disease.</p><p>Use in adults The recommended dose of Spectrila for adults is 5,000 U per m body surface area (BSA) given every third day.</p><p>Use in children and adolescents The recommended dose in children and adolescents aged 1 18 years is 5,000 U per m BSA given every third day.</p><p>The recommended dose in infants aged 0 12 months is as follows:</p><ul><li>age less than 6 months: 6,700 U/m BSA,</li><li>age 6 12 months:<br/>7,500 U/m BSA.</li></ul><p>If you were given more Spectrila than you should If you think that you received too much Spectrila, tell your doctor or nurse as soon as possible.</p><p>Up to date it is not known that an overdose with asparaginase led to any signs of an overdose. If necessary, your doctor will treat your symptoms and will give you supportive care.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately and stop taking Spectrila if you experience:</p><ul><li>inflammation of the pancreas, which causes severe pain in the abdomen and back,</li><li>severe liver function abnormalities (determined by laboratory tests),</li><li>allergic reactions including serious allergic reaction (anaphylactic shock), flushing, rash, low blood pressure, swelling of face and throat, hives, shortness of breath,</li><li>blood clotting disorders such as bleeding, disseminated intravascular coagulation (DIC) or formation of blood clots (thrombosis),</li><li>high blood sugar level (hyperglycaemia).</li></ul><p>A list of all other side effects is set out below according to how common they are:</p><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>feeling sick (nausea), being sick (vomiting), stomachache or watery stools (diarrhoea)</li><li>accumulation of fluid (oedema)</li><li>feeling of tiredness</li><li>abnormal laboratory tests including changes in protein levels in the blood, changes in blood fat or in liver enzyme values or high level of urea in the blood</li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>mild to moderate reduction in all blood cell counts</li><li>allergic reactions including wheezing (bronchospasm) or difficulty in breathing</li><li>low blood sugar level (hypoglycaemia)</li><li>loss of appetite or weight loss</li><li>depression, hallucination or confusion</li><li>nervousness (agitation) or somnolence (sleepiness)</li><li>changes in the electroencephalogram (a trace of the electrical activity of your brain)</li><li>high blood levels of amylase and lipase</li><li>pain (back pain, joint pain, stomach ache)</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>high blood levels of uric acid (hyperuricaemia)</li><li>high blood levels of ammonia (hyperammonaemia)</li><li>headache</li></ul><p>Rare (may affect up to 1 in 1,000 people)</p><ul><li>diabetic ketoacidosis (complication due to uncontrolled blood sugar)</li><li>seizures, severe impairment of consciousness including coma, and stroke</li><li>reversible posterior leukoencephalopathy syndrome (a condition characterised by headache, confusion, seizures and visual loss)</li><li>inflammation of the salivary glands (parotitis)</li><li>cholestasis (blocked bile flow from the liver)</li><li>jaundice</li><li>destruction of liver cells (liver cell necrosis)</li><li>liver failure which may lead to death</li></ul><p>Very rare (may affect up to 1 in 10,000 people)</p><ul><li>decreased function of the thyroid gland or the parathyroid glands</li><li>mild tremor (shaking) of the fingers</li><li>pseudocysts of the pancreas (collections of fluid after acute inflammation of the pancreas)</li></ul><p>Not known (frequency cannot be estimated from the available data):</p><ul><li>infections</li><li>fatty liver</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store spectrila",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store spectrila"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C 8 C). Keep the vial in the outer carton in order to protect from light.</p><p>The reconstituted solution is stable for 2 days when stored at 2 C 8 C. If the medicine is not used immediately, the user preparing this medicine is responsible for storage times and conditions to ensure sterility of the product. Storage would normally not be longer than 24 hours at 2 C 8 C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Spectrila contains</p><ul><li>The active substance is asparaginase. One vial of powder contains 10,000 units of asparaginase. After reconstitution, one ml of solution contains 2,500 units of asparaginase.</li><li>The other ingredient is sucrose.</li></ul><p>What Spectrila looks like and contents of the pack Spectrila is provided as a powder for concentrate for solution for infusion.</p><p>The powder is white and it is supplied in a clear glass vial with a rubber stopper and an aluminium seal and a plastic flip-off cap.</p><p>Spectrila is available in packs containing 1 or 5 vials. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer medac<br/>Gesellschaft f r klinische Spezialpr parate mbH Theaterstr. 6 22880 Wedel Germany Tel.: +49-4103-8006-0 Fax: +49-4103-8006-E-mail: <a href=\"mailto:contact@medac.de\">contact@medac.de</a></p><p>This leaflet was last revised in {MM/YYYY}.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp2440cbc7bcf5f09685459c4222f929e1",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp2440cbc7bcf5f09685459c4222f929e1",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp2440cbc7bcf5f09685459c4222f929e1\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp2440cbc7bcf5f09685459c4222f929e1</b></p><a name=\"mp2440cbc7bcf5f09685459c4222f929e1\"> </a><a name=\"hcmp2440cbc7bcf5f09685459c4222f929e1\"> </a><a name=\"mp2440cbc7bcf5f09685459c4222f929e1-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1072/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Spectrila 10,000 U powder for concentrate for solution for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/15/1072/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Spectrila 10,000 U powder for concentrate for solution for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
